Showing results (61-70 of 159) with videos related to

Sort By:
Pageof 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 21, 2019
Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?Sima L Sharara, Joe Amoah, Zoi D Pana, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2024
Assessing the impact of meropenem exposure on ceftolozane/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passageAliaa Fouad, Samantha E Nicolau, Pranita D Tamma, et al.
Antimicrobial Agents and Chemotherapy|May 30, 2019
The Likelihood of Developing a Carbapenem-Resistant <i>Enterobacteriaceae</i> Infection during a Hospital StayPranita D Tamma, Abida Kazmi, Yehudit Bergman, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|June 11, 2021
Combined selective culture and molecular methods for the detection of carbapenem-resistant organisms from fecal specimensRebecca Yee, Stefanie Fisher, Yehudit Bergman, et al.
Open Forum Infectious Diseases|June 8, 2018
Using Patient Risk Factors to Identify Whether Carbapenem-Resistant <i>Enterobacteriaceae</i> Infections Are Caused by Carbapenemase-Producing OrganismsPatricia J Simner, Katherine E Goodman, Karen C Carroll, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 26, 2016
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae BacteremiaPranita D Tamma, Katherine E Goodman, Anthony D Harris, et al.
Journal of Clinical Microbiology|October 4, 2023
Updating breakpoints in the United States: a summary from the ASM Clinical Microbiology Open 2022Jean B Patel, Kevin Alby, Romney Humphries, et al.
Pageof 16